Fig. 7
From: MLKL-mediated necroptosis is a target for cardiac protection in mouse models of type-1 diabetes
Effects of MLKL knockdown in streptozocin (STZ)-induced diabetic hearts. Akita mice received two separate doses of shRNA for MLKL on day 0 and day 3, respectively. Wild-type mice (WT) served as Sham. Control Akita mice received same amounts of an empty plasmid. On day 5, mice were sacrificed. a The levels of MLKL protein were analyzed by western blot in the heart. Upper panel: a representative western blot from 4 out of 6 different hearts in each group for MLKL and GAPDH; Bottom panel: quantification of MLKL relative to GAPDH protein. b Necrotic cell death in the heart was determined by Evans blue staining assay. Upper panel: representative micro-photograph for necrotic cells in the heart; Bottom panel: quantification of necrotic cell death. c Biomarker of myocardial injury: serum cardiac troponin I. d Body weight and blood glucose levels in Akita mice on day 0 and day 5. Data are mean ± SD, n = 6. *P < 0.05 versus Control and †P < 0.05 versus Control + Akita (t test and ANOVA)